SeaStar Medical Announces Positive Results from Pilot Clinical Study of the Selective Cytopheretic Device (SCD) in Pediatric Patients with Acute Kidney Injury
Study met primary and secondary endpoints related to survival and renal recovery at day 60. DENVER, Oct. 26, 2020 /PRNewswire/ — SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, today announced the results from the first every application of the Selective Cytopheretic Device (SCD) in pediatric patients with acute kidney injury […]
SeaStar Medical to present Data on Selective Cytopheretic Device (SCD) in Pediatric Patients with Acute Kidney Injury at American Society of Nephrology Kidney Week 2020
DENVER (PRWEB) OCTOBER 13, 2020 SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, today announced it will present Phase II clinical trial outcomes of its Selective Cytopheretic Device (SCD) at the virtual American Society of Nephrology (ASN) Kidney Week 2020 meeting which will take place October 22-25, 2020. The […]
SeaStar Medical Appoints New Board Chairman To Deliver Growth
DENVER, May 21, 2020 /PRNewswire/ — SeaStar Medical, a medical device company focused on delivering novel immunomodulating medical device solutions to improve organ function, today announced the appointment of Ray Chow as chairman of its Board of Directors. Ray will lead the Board, working with the existing investors and any future investment groups. In addition, Ray will oversee Business […]
Ohio State Uses Experimental Therapy to Combat Excess Inflammation in COVID-19 Patients
COLUMBUS, Ohio – Researchers at The Ohio State University Wexner Medical Center are the first in Ohio to test a therapy that reduces the uncontrolled inflammation in COVID-19 patients that has been linked to severe respiratory distress, heart inflammation, multi-organ failure and death. Using the SeaStar Medical CLR 2.0 filter, doctors are filtering patient blood to […]
SeaStar Medical to Initiate a Pilot Study of Selective Cytopheretic Device in COVID-19 patients with Acute Respiratory Distress Syndrome and Acute Kidney Injury
Trial will test clinical activity, safety and efficacy of novel immunomodulating medical device to reverse and repair organ injury. DENVER, April 28, 2020 /PRNewswire/ — SeaStar Medical, a medical device company focused on delivering novel immunomodulating medical device solutions to improve organ function, today announced it has received approval of their Investigational Device Exemption (IDE) supplement from […]